Physician profile
Inessa Krel
NPI 1104286061
$10,874.16
in general payments reported to CMS, 2019-2025
40 companies · $2,061 in 2025
The $2,061 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,251 · 2022: $2,322 · 2023: $2,077 · 2024: $2,162 · 2025: $2,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,301.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,069.02 | 2021-2025 | Descovy, Yeztugo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,355.10 | 2021-2025 | Jardiance |
| Abbvie INC. | $1,229.61 | 2021-2025 | |
| Lilly USA, LLC | $941.30 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Corium, LLC | $809.96 | 2022-2025 | Azstarys |
| Sanofi-Aventis U.S. LLC | $556.26 | 2021-2023 | |
| Neos Therapeutics, LP | $531.80 | 2021-2024 | Adzenys Xr-Odt |
| Axsome Therapeutics, INC. | $411.98 | 2024-2025 | Auvelity |
| Glaxosmithkline, LLC. | $403.72 | 2021-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $326.89 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $257.39 | 2024-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $236.60 | 2022-2023 | Qelbree |
| Bayer Healthcare Pharmaceuticals INC. | $199.29 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $143.26 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $141.05 | 2022-2023 | Quviviq |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inessa Krel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.